Cargando…

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

BACKGROUND: In spite of increasing efforts to enhance patient safety, medication errors in hospitalised patients are still relatively common, but with potentially severe consequences. This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranchon, Florence, Salles, Gilles, Späth, Hans-Martin, Schwiertz, Vérane, Vantard, Nicolas, Parat, Stéphanie, Broussais, Florence, You, Benoît, Tartas, Sophie, Souquet, Pierre Jean, Dussart, Claude, Falandry, Claire, Henin, Emilie, Freyer, Gilles, Rioufol, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262863/
https://www.ncbi.nlm.nih.gov/pubmed/22067636
http://dx.doi.org/10.1186/1471-2407-11-478
_version_ 1782221782288171008
author Ranchon, Florence
Salles, Gilles
Späth, Hans-Martin
Schwiertz, Vérane
Vantard, Nicolas
Parat, Stéphanie
Broussais, Florence
You, Benoît
Tartas, Sophie
Souquet, Pierre Jean
Dussart, Claude
Falandry, Claire
Henin, Emilie
Freyer, Gilles
Rioufol, Catherine
author_facet Ranchon, Florence
Salles, Gilles
Späth, Hans-Martin
Schwiertz, Vérane
Vantard, Nicolas
Parat, Stéphanie
Broussais, Florence
You, Benoît
Tartas, Sophie
Souquet, Pierre Jean
Dussart, Claude
Falandry, Claire
Henin, Emilie
Freyer, Gilles
Rioufol, Catherine
author_sort Ranchon, Florence
collection PubMed
description BACKGROUND: In spite of increasing efforts to enhance patient safety, medication errors in hospitalised patients are still relatively common, but with potentially severe consequences. This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs. METHODS: A 1-year prospective study was conducted in order to identify the medication errors that occurred during chemotherapy treatment of cancer patients at a French university hospital. The severity and potential consequences of intercepted errors were independently assessed by two physicians. A cost analysis was performed using a simulation of potential hospital stays, with estimations based on the costs of diagnosis-related groups. RESULTS: Among the 6, 607 antineoplastic prescriptions, 341 (5.2%) contained at least one error, corresponding to a total of 449 medication errors. However, most errors (n = 436) were intercepted before medication was administered to the patients. Prescription errors represented 91% of errors, followed by pharmaceutical (8%) and administration errors (1%). According to an independent estimation, 13.4% of avoided errors would have resulted in temporary injury and 2.6% in permanent damage, while 2.6% would have compromised the vital prognosis of the patient, with four to eight deaths thus being avoided. Overall, 13 medication errors reached the patient without causing damage, although two patients required enhanced monitoring. If the intercepted errors had not been discovered, they would have resulted in 216 additional days of hospitalisation and cost an estimated annual total of 92, 907€, comprising 69, 248€ (74%) in hospital stays and 23, 658€ (26%) in additional drugs. CONCLUSION: Our findings point to the very small number of chemotherapy errors that actually reach patients, although problems in the chemotherapy ordering process are frequent, with the potential for being dangerous and costly.
format Online
Article
Text
id pubmed-3262863
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32628632012-01-21 Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs Ranchon, Florence Salles, Gilles Späth, Hans-Martin Schwiertz, Vérane Vantard, Nicolas Parat, Stéphanie Broussais, Florence You, Benoît Tartas, Sophie Souquet, Pierre Jean Dussart, Claude Falandry, Claire Henin, Emilie Freyer, Gilles Rioufol, Catherine BMC Cancer Research Article BACKGROUND: In spite of increasing efforts to enhance patient safety, medication errors in hospitalised patients are still relatively common, but with potentially severe consequences. This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs. METHODS: A 1-year prospective study was conducted in order to identify the medication errors that occurred during chemotherapy treatment of cancer patients at a French university hospital. The severity and potential consequences of intercepted errors were independently assessed by two physicians. A cost analysis was performed using a simulation of potential hospital stays, with estimations based on the costs of diagnosis-related groups. RESULTS: Among the 6, 607 antineoplastic prescriptions, 341 (5.2%) contained at least one error, corresponding to a total of 449 medication errors. However, most errors (n = 436) were intercepted before medication was administered to the patients. Prescription errors represented 91% of errors, followed by pharmaceutical (8%) and administration errors (1%). According to an independent estimation, 13.4% of avoided errors would have resulted in temporary injury and 2.6% in permanent damage, while 2.6% would have compromised the vital prognosis of the patient, with four to eight deaths thus being avoided. Overall, 13 medication errors reached the patient without causing damage, although two patients required enhanced monitoring. If the intercepted errors had not been discovered, they would have resulted in 216 additional days of hospitalisation and cost an estimated annual total of 92, 907€, comprising 69, 248€ (74%) in hospital stays and 23, 658€ (26%) in additional drugs. CONCLUSION: Our findings point to the very small number of chemotherapy errors that actually reach patients, although problems in the chemotherapy ordering process are frequent, with the potential for being dangerous and costly. BioMed Central 2011-11-08 /pmc/articles/PMC3262863/ /pubmed/22067636 http://dx.doi.org/10.1186/1471-2407-11-478 Text en Copyright ©2011 Ranchon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ranchon, Florence
Salles, Gilles
Späth, Hans-Martin
Schwiertz, Vérane
Vantard, Nicolas
Parat, Stéphanie
Broussais, Florence
You, Benoît
Tartas, Sophie
Souquet, Pierre Jean
Dussart, Claude
Falandry, Claire
Henin, Emilie
Freyer, Gilles
Rioufol, Catherine
Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
title Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
title_full Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
title_fullStr Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
title_full_unstemmed Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
title_short Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
title_sort chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262863/
https://www.ncbi.nlm.nih.gov/pubmed/22067636
http://dx.doi.org/10.1186/1471-2407-11-478
work_keys_str_mv AT ranchonflorence chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT sallesgilles chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT spathhansmartin chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT schwiertzverane chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT vantardnicolas chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT paratstephanie chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT broussaisflorence chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT youbenoit chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT tartassophie chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT souquetpierrejean chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT dussartclaude chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT falandryclaire chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT heninemilie chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT freyergilles chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts
AT rioufolcatherine chemotherapeuticerrorsinhospitalisedcancerpatientsattributabledamageandextracosts